Takeda Pharmaceutical Co. Ltd. (TAK, TKPYY.PK) announced Tuesday the results from the TOURMALINE-MM2 study designed to evaluate the addition of NINLARO (ixazomib) to lenalidomide and dexamethasone in newly diagnosed transplant ineligible multiple myeloma patients.
from RTT - Biotech https://ift.tt/2v95p1k
via IFTTT
No comments:
Post a Comment